Hospital admissions linked to unapproved weight-loss peptide Retatrutide are rising as gym-goers purchase the experimental drug online, according to leading obesity consultant Professor Donal O’Shea. The injectable peptide, currently undergoing clinical trials by Eli Lilly, has not received regulatory approval anywhere in the world and cannot be sold legally in Ireland or other markets, yet it has gained widespread popularity among individuals seeking rapid fat loss through social media and personal trainers.
Hospitalizations Rise Due to Unregulated Retatrutide Use
Medical professionals are treating a growing number of patients suffering severe gastrointestinal and systemic side effects after obtaining Retatrutide outside clinical settings. According to Professor O’Shea, patients frequently receive the drug twice a week in gym environments on the advice of personal trainers who fail to provide guidance on managing adverse reactions. In one recent case reported by Professor O’Shea, a patient required hospitalization for severe vomiting and kidney disease after receiving twin weekly injections from a trainer. Common side effects of the drug include nausea, vomiting, diarrhoea, and constipation, alongside potential impacts on the liver, pancreas, and kidneys. Furthermore, Professor O’Shea noted that some patients conceal their use of the drug out of embarrassment, leaving medical staff blindfolded when attempting to diagnose acute illnesses.
Did you know? Retatrutide is an injectable peptide currently undergoing clinical trials by Eli Lilly and is not approved for human use anywhere in the world.
Personal Accounts Highlight Severe Physical Toll
Online fitness coaches and gym users have shared severe physiological reactions after injecting the drug to accelerate weight loss ahead of physical events. Shauna Louise Cleary, an online fitness coach, began using Retatrutide in February ahead of a photoshoot in Marbella after learning about it within the bodybuilding community. According to Ms Cleary, she injected the substance twice a week, which triggered severe physical rejection within two weeks. Within half an hour of injection, she experienced debilitating sickness and an inability to stand, restricting her dietary intake to under 500 calories a day as all food was immediately expelled. After increasing her dosage, Ms Cleary nearly collapsed in the gym and subsequently stopped taking the peptide, concluding that the extreme stress placed on her body was unjustified.
Regulatory Bodies and Social Media Crackdowns
Technology platforms and health regulators are attempting to curb the illicit online trade of unapproved weight-loss substances, though enforcement remains challenging. Earlier this month, Eli Lilly called on social media companies to stop enabling the illegal market and block prohibited conduct before it reaches consumers. Meta reported that it removes weight-loss content containing miracle claims, attempts to buy or sell products often advertised as ‘peps’, and instructions for non-medical drugs. Similarly, TikTok stated it bans trading, marketing, or providing access to regulated weight-loss or muscle-gain substances, noting that it has banned hashtags including #retatrutide and #reta. Despite these measures, RTÉ News observed that several social media accounts continue to bypass restrictions, while the Health Products Regulatory Authority reported a continual upward trend in social media pages illegally marketing weight-loss drugs.
FDA Warnings on Unapproved GLP-1 and Compounded Drugs
Parallel regulatory actions in the United States highlight broader safety risks associated with unapproved and compounded alternatives in the GLP-1 class. According to the U.S. Food and Drug Administration (FDA), unapproved versions of GLP-1 receptor agonists do not undergo rigorous agency review for safety, effectiveness, and quality before marketing. Federal law explicitly prohibits the use of Retatrutide and cagrilintide in drug compounding, and these agents are not components of any FDA-approved medications. The FDA has issued warning letters to telehealth companies, active pharmaceutical ingredient distributors, and outsourcing facilities regarding the direct marketing and distribution of unapproved Retatrutide. Additionally, the agency established a green list import alert to block substandard active pharmaceutical ingredients from entering supply chains and warned that improper shipping temperatures can compromise injectable peptide quality.
Pro Tip: Healthcare authorities advise anyone using GLP-1 or related peptide drugs who experiences acute illness to seek immediate medical attention and fully disclose their usage to treating physicians.
Frequently Asked Questions
Is Retatrutide approved for human use?
No. Retatrutide is currently undergoing clinical trials by Eli Lilly and is not approved for human use by any regulatory authority worldwide, according to health agencies.
What are the primary side effects of Retatrutide?
The most common side effects are gastrointestinal, including severe nausea, vomiting, diarrhoea, and constipation. The drug can also adversely affect liver, pancreas, and kidney function, frequently resulting in hospitalizations when taken without medical supervision.
How are people obtaining Retatrutide illegally?
Users typically source the unapproved peptide online, through social media networks, or via personal trainers and unregulated fitness communities, despite active enforcement measures and hashtag bans by platforms like Meta and TikTok.
Why do medical professionals urge patients to disclose Retatrutide use?
According to Professor Donal O’Shea, patients suffering from side effects are often too embarrassed to admit they are injecting unapproved peptides, which leaves hospital staff blindfolded when diagnosing and treating acute conditions like kidney disease and severe vomiting.
Have you or someone you know been affected by unapproved weight-loss drugs? Leave a comment below or subscribe to our newsletter for ongoing updates on public health and medical safety.
Keep reading